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Chronic myeloid leukemia (CML) is caused by 
the (9;22) translocation leading to the formation of the 
constantly active BCR-ABL fusion kinase. Tyrosine kinase 
inhibitors (TKIs) block the function of the oncokinase, and 
the use of TKIs has considerably improved the treatment 
responses in CML. Even though TKI treatment in CML 
has been a success, the long-term use may cause severe 
adverse effects which impact the quality of life and may 
cause additional morbidity. In addition, due to the high 
cost of the TKI therapy the lifelong treatment causes 
economic burden. 
Several studies have shown that nearly half of 
the CML patients who have reached deep, durable 
molecular remission can stop the TKI treatment and stay 
in remission [1]. However, with the sensitive detection 
of BCL-ABL1 from the blood, it has been demonstrated 
that residual leukemic cells still exist in the patients who 
stay in remission without any treatment [2]. Although the 
immune system has been shown to be dysfunctional in 
newly diagnosed CML patients, TKI therapy may restore 
the function of the immune cells [3], and thus, the immune 
system may play a role in the leukemia control. To be able 
to select the best candidates for TKI stopping, it would be 
important to understand the biology behind a successful 
TKI discontinuation. 
In the recent study, we evaluated in detail the 
phenotype and function of different immune cell subsets 
in CML patients who aimed to stop the TKI therapy [4]. 
Our results showed that at the time of TKI discontinuation 
patients who stayed in remission had more mature NK 
cells in peripheral blood expressing CD57 and CD16 
antigens compared to the patients who relapsed within 
6 months after imatinib stopping. In accordance, the 
proportion of CD56bright naïve NK-cells was associated 
with molecular relapse. When analysing the clinical 
paramaters, we noticed that the proportion of NK cells 
was not related to CML risk score (Sokal score), previous 
IFN-α treatment or the duration of TKI treatment. Similar 
observations have also been made by other groups [5, 
6]. Interestingly, we have also earlier shown that NK 
cells, Th1 type of response and memory T cells (both 
CD4+ and CD8+) are increased in CML patients who 
have been able to discontinue IFN-alpha monotherapy 
and stay in remission [7]. Similarly, in the current study 
where patients were treated with TKIs, the high NK cell 
proportion was accompanied with increased Th1 response 
of CD4+ T cells (TNF-α/IFN-γ production). 
The classical NK cells are considered to be a part 
of the innate immunity. However, recent studies have 
demonstrated that NK cells are capable of persisting for 
a long time and executing memory-like functions which 
lead to a strong immune response when the same target 
is encountered the second time. These so-called adaptive 
NK cells have downregulated certain signalling molecules 
and transcription factors such as FcεRγ, PLZF, SYK, EAT-
2. Interestingly, the mature NK cells in CML patients in 
remission after TKI discontinuation seemed to have 
also downregulated some of the typical adaptive NK-
cell markers (such as EAT-2). In the follow-up samples 
after the imatinib discontinuation, we also noticed the 
phenotype and the amount of NK cells persisted similar as 
before the TKI discontinuation. Therefore, it is tempting 
to hypothesize that these putative adaptive-like NK cells 
contribute to the anti-leukemic attacks.
However, the immune system is complex and 
the role of other immune cell subsets is still unclear, 
although we could not detect clear association between 
other cells analysed and successful TKI discontinuation. 
Schutz et al. [8] have studied the dendritic cells (DC) 
from CML patients who discontinued TKI treatment. 
They demonstrated that the plasmocytoid DCs (pDCs) 
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Figure 1: Schematic figure of the suggested hypothetical 
mechanism of anti-leukemia immunity in patients who 
have successfully discontinued TKI or IFN-α treatment. 
Antigen presenting cells (APCs) secrete cytokines which together 
with the leukemia cell induced activation could induce NK cell 
proliferation. Repeated stimulus may shift NK cells towards more 
mature, adaptive phenotype. NK cells could execute either direct 
killing of the leukemic cells or alternatively drive T cells to a more 
effective leukemia targeting state.
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expressing CD86 (the ligand for CTLA4) were associated 
with the exhausted CD8+ T-cell phenotype and molecular 
relapse. This could be one of the immune escape 
mechanisms of CML. Based on these different studies the 
interaction between NK cells and pDCs should be further 
studied. 
Taken together, these results suggest that the 
putative anti-leukemia immunity observed as increased 
amount of NK cells could function through various 
mechanisms including both adaptive (modulation of T-cell 
responses) and innate immunity (direct killing effects) 
(Figure 1). Additional immune escape mechanisms 
employed by leukemic cells should be further studied 
when aiming at the curative treatment strategies in CML. 
NK cell modulating agents are already in clinical trials 
in other haematological malignancies and their testing 
in CML is warranted. These approaches could result in 
increased proportion of patients who can discontinue TKI 
treatment and therefore be closer to the cure.
Satu Mustjoki: Hematology Research Unit Helsinki, 
Department of Clinical Chemistry and Hematology, 
University of Helsinki and Helsinki University Hospital 
Comprehensive Cancer Center, Helsinki, Finland
Correspondence to: Satu Mustjoki, email satu.mustjoki@hel-
sinki.fi
Keywords: chronic myeloid leukemia; NK cells; immunology; 
biomarker and tyrosine kinase inhibitor 
Received: September 11, 2017
Published: November 03, 2017
REFERENCES
1. Mahon FX, et al. Lancet Oncol. 2010; 11:1029-35.
 https://doi.org/10.1016/S1470-2045(10)70233-3.
2. Ross DM, et al. Blood. 2013; 122:515-22.
 https://doi.org/10.1182/blood-2013-02-483750.
3. Hughes A, et al. Blood. 2017; 129:1166-76.
 https://doi.org/10.1182/blood-2016-10-745992.
4. Ilander M, et al. Leukemia. 2017; 31:1108-16.
 https://doi.org/10.1038/leu.2016.360.
5. Rea D, et al. Haematologica. 2017; 102:1368-77.
 https://doi.org/10.3324/haematol.2017.165001.
6. Imagawa J, et al. Lancet Haematol. 2015; 2:e528-35.
 https://doi.org/10.1016/S2352-3026(15)00196-9.
7. Ilander M, et al. PLoS One. 2014; 9:e87794.
 https://doi.org/10.1371/journal.pone.0087794.
8. Schutz C, et al. Leukemia. 2017; 31:829-36.
 https://doi.org/10.1038/leu.2017.9.
Copyright: Ilander et al. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License 3.0 
(CC BY 3.0), which permits unrestricted use, distribution, and re-
production in any medium, provided the original author and source 
are credited.
